Biochemicals & reagents
1) Buchdunger, et al.(1996) Inhibition of the Abl Protein-Tyrosine Kinase in Vitro and in Vivo by a 2-Phenylpyrimidine Derivative; Cancer Res. 56, 100 / 2) Heinrich et al (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 925.
493.62 ∙ 96.11
Imatinib is a tyrosine kinase inhibitor specific for abl (IC50 = 0.038 µM) (1), for PDGF-R (IC50 = 0.3 µM) (1) and for c-kit (IC50 = 0.1 µM) (2). This compound is a clinically relevant anti-cancer drug approved for the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors as well as several other cancers.